Days
Hours
Minutes
Seconds
-40%
on all subscriptions*
Exceptional extension!
Enjoy this offer
* See conditions under "Our services"
Manager TitleAgeSince
President 61 01/06/2023
Chief Tech/Sci/R&D Officer - -
Chief Tech/Sci/R&D Officer - 01/01/2021
Date Insider Type Main position Quantity % Market Cap.
01/06/23
MPM BioImpact LLC
OthersCompany 4,158,964 10.5929%
01/06/23Issuer sale

Director

60,342 0.1537%
01/06/23
Tang Capital Management LLC
OthersCompany 4,394,800 11.1936%
Change 5-day change 1-year change 3-year change Capi.($)
-5.73%-15.43% - - 58.11M
+0.34%+2.06%-10.67%-5.26% 43.13B
+1.73%+3.59%+314.11%+564.04% 34.65B
+0.61%+1.34%+5.55%+46.20% 30.03B
+0.02%-5.93%+8.15%-21.44% 28B
-1.06%-2.60%+9.08%+21.51% 24.45B
-1.23%+2.11% - - 14.34B
-0.99%-2.53%+47.63%+102.88% 13.14B
+1.54%-0.94%+6.69%+8.40% 12.53B
+2.39%+2.61%+101.46%+84.20% 12.25B
Average -0.39%+0.65%+60.25%+100.06% 23.61B
Weighted average by Cap. +0.16%+1.19%+65.56%+116.65%
Logo TCR2 Therapeutics Inc.
TCR2 Therapeutics Inc. is a clinical-stage immunotherapy company developing T cell therapies for patients suffering from cancer. The Company's T cell receptor (TCR) Fusion Construct T cells (TRuC-T cells) specifically recognize and kill cancer cells by harnessing the entire T cell receptor (TCR) signaling complex. Its lead TRuC-T cell, which targets solid tumors is gavocabtagene autoleucel (gavo-cel). The Company completed the Phase I portion of its Phase I/II clinical trial for gavo-cel to treat patients with non-small cell lung cancer (NSCLC), ovarian cancer, malignant pleural/peritoneal mesothelioma and cholangiocarcinoma. Its other product candidates include TC-510 and TC-520. Its TC-510 is a TRuC-T cell targeting mesothelin-expressing solid tumors which incorporates a PD-1:CD28 chimeric switch receptor. Its TC-520 is the Company's TRuC-T cell targeting CD-70-expressing solid and liquid tumors which incorporates IL-15 pathway enhancements designed to improve T-cell persistence.
Employees
58
  1. Stock Market
  2. Stocks
  3. TCRR Stock
-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!